(function(){var loadHandler=window['sl_{D0ADD9BC-5BCE-4B01-85F9-188A7AEC90E6}'];loadHandler&&loadHandler(180, '<div id="spr0_aefa1b4"><div id="spr1_aefa1b4" class="kern slide"><img id="img1_aefa1b4" src="data/img2.png" width="720px" height="540px" alt="" style="left:0px;top:0px;"/></div><div id="spr2_aefa1b4" class="kern slide"><div id="spr3_aefa1b4" style="left:103.125px;top:165.786px;"><img id="img0_aefa1b4" src="data/img263.png" width="513.75" height="343.5" alt=""/></div><div id="spr4_aefa1b4" style="top:105.2px;"><div style="width:0px;"><span id="txt0_aefa1b4" data-width="401.132813" style="left:161.478px;top:0.564px;">Letrozole + Trastuzumab (HER2 inhibitor)</span></div><div style="width:0px;"><span id="txt1_aefa1b4" data-width="323.408203" style="left:198.672px;top:29.87px;">ER+ve HER2+ve advanced breast cancer</span></div></div><div id="spr5_aefa1b4" style="left:256.153px;top:518.189px;"><div style="width:0px;"><span id="txt2_aefa1b4" data-width="185.068359" style="left:7.2px;top:2.082px;">J. Huober et al. 2012 The Breast 21:27</span></div></div><div id="spr6_aefa1b4" style="top:57.765px;"><div style="width:0px;"><span id="txt3_aefa1b4" data-width="671.548828" style="left:25.888px;top:0.058px;">combining endocrine treatments with new targeted agents</span></div></div><div id="spr7_aefa1b4" style="top:13.601px;"><div style="width:0px;"><span id="txt4_aefa1b4" data-width="204.626953" style="left:144.246px;top:0.058px;">Biomarker-guided</span></div></div></div></div>');})();